Your search for pancreatic cancer matches 235 pages

Showing 151 - 200


pancreatic cancer

Preclinical Study Reveals Why Chemotherapy May Be Compromised in Patients With Pancreatic Cancer

A study at The University of Texas MD Anderson Cancer Center may explain why chemotherapy drugs such as gemcitabine are not effective for many patients with pancreatic cancer and perhaps point to new approaches to treatment, including enhancing gemcitabine's ability to stop tumor growth. The MD...

pancreatic cancer
issues in oncology

Only 1 in 5 U.S. Patients With Pancreatic Cancer Gets Key Blood Test at Diagnosis

Only 1 in 5 patients with pancreatic cancer in the United States receives a widely available, inexpensive blood test at diagnosis that can help predict relative outcome (compared to others with the same disease stage) and guide treatment accordingly, a Mayo Clinic study showed. People who test...

pancreatic cancer

Immunotherapy for Pancreatic Cancer Boosts Survival by More Than 75% in Preclinical Models

A new study in mice by researchers at Fred Hutchinson Cancer Research Center has found that a specialized type of immunotherapy—even when used without chemotherapy or radiation—can boost survival from pancreatic cancer by more than 75%. The findings are promising, and human clinical...

pancreatic cancer

FDA Approves Liposomal Irinotecan for Advanced Pancreatic Cancer

The U.S. Food and Drug Administration today approved irinotecan liposome injection (Onivyde), in combination with fluorouracil (5-FU) and leucovorin, to treat patients with metastatic pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy. According to the National...

pancreatic cancer

Ruxolitinib-Capecitabine May Benefit Patients With Gemcitabine-Pretreated Metastatic Pancreatic Cancer With Systemic Inflammation

In a randomized phase II trial reported in the Journal of Clinical Oncology, Hurwitz et al found no significant survival benefit of adding the JAK1/JAK2 inhibitor ruxolitinib (Jakafi) to capecitabine in patients with advanced pancreatic adenocarcinoma who had treatment failure with gemcitabine....

pancreatic cancer

Pancreatic Cancer Action Network and AACR Invite Applications for 2016 Research Grants

The American Association for Cancer Research (AACR) and the Pancreatic Cancer Action Network announced the opening of the 2016 Research Grants Program to support early-career investigators to focus on pancreatic cancer. Two grant mechanisms, the Pathway to Leadership Grant and the Career...

issues in oncology
pancreatic cancer
issues in oncology

MicroRNA Panel Shows Early Potential as Biomarker of Pancreatic Precancers

Assessing blood plasma levels of certain microRNAs (miRNAs) distinguished individuals with noninvasive pancreatic precancers from healthy individuals and discriminated between patients with high-risk and low-risk neoplasms, according to a preliminary, proof-of-principle study published by...

issues in oncology
pancreatic cancer
issues in oncology
issues in oncology

Study Identifies Genes Associated With Improved Survival for Patients With Pancreatic Cancer

A multi-institutional study has found a new set of genes that may indicate improved survival after surgery for patients with pancreatic cancer. The study also showed that detection of circulating tumor DNA in the blood could provide an early indication of tumor recurrence. In conjunction with the...

issues in oncology
pancreatic cancer

Researchers Identify Nerve-Guiding Protein That May Be Associated With Pancreatic Cancer Metastasis

Scientists at the Johns Hopkins Kimmel Cancer Center have identified a molecular partnership in pancreatic cancer cells that might help to explain how the disease metastasizes in some cases. Their findings reveal urgently needed new targets to treat pancreatic cancer and were published by Foley et...

issues in oncology
pancreatic cancer
issues in oncology

Proteins Found in Urine May Serve as Biomarker for Early-Stage Pancreatic Cancer

A team of researchers at Barts Cancer Institute­­–Queen Mary University of London has discovered a combination of three proteins found at high levels in urine that can accurately detect early-stage pancreatic cancer. The discovery could lead to a noninvasive, inexpensive test to...

solid tumors
pancreatic cancer
prostate cancer
bladder cancer

Analysis Suggests Use of Pioglitazone for Diabetes May Increase Risk of Prostate and Pancreatic Cancers But Not Bladder Cancer

Available data suggest an increased risk of bladder cancer with pioglitazone treatment for diabetes. In an analysis of Kaiser Permanente Northern California data reported in JAMA, Lewis et al found no significantly increased risk of bladder cancer in patients with diabetes ever using pioglitazone....

pancreatic cancer
prostate cancer

Study Identifies Mechanism Fueling Growth of Pancreatic and Prostate Cancer Cells

UCLA Jonsson Cancer Center scientists have identified a new mechanism that delivers a key substance that fuels the growth of pancreatic and prostate cancer cells, a finding that offers new hope in the fight against two of the deadliest forms of the disease. Their findings were published by...

issues in oncology
pancreatic cancer
issues in oncology
issues in oncology

Protein-Enriched Exosome Useful for Early Diagnosis of Pancreatic Cancer

A protein encoded by the gene glypican-1 (GPC1) present on cancer exosomes may be used as part of a potential noninvasive diagnostic and screening tool to detect early pancreatic cancer, potentially at a stage amenable to surgical treatment, according to a study completed by University of Texas MD...

pancreatic cancer

Dutch Study Indicates No Survival Benefit of Adding Metformin to Gemcitabine-Erlotinib in Advanced Pancreatic Cancer

In a Dutch phase II study reported in The Lancet Oncology, Kordes et al found that adding metformin to gemcitabine-erlotinib (Tarceva) did not improve overall survival in patients with advanced pancreatic cancer. Study Details In the double-blind study, 121 patients from four centers in the...

colorectal cancer
solid tumors
pancreatic cancer
supportive care

ESMO World GI 2015: SENRI Trial Evaluates NK1 Antagonists for Emesis Prevention in Oxaliplatin-Based Chemotherapy

The SENRI trial has opened the window to evaluate neurokinin 1 (NK1) antagonists for emesis prevention in patients taking oxaliplatin chemotherapy, said European Society for Medical Oncology World Congress on Gastrointestinal Cancer (ESMO) spokesperson and antiemetics expert Fausto Roila, MD....

pancreatic cancer

Boosted Radiation Dose May Make Some Pancreatic Cancers Resectable

Because of their location, cancers on the pancreas often invade and wrap around nearby veins and arteries in the abdomen. When these vessels become involved, surgery to remove the cancer, which is typically the standard treatment, becomes significantly more difficult—sometimes impossible....

hematologic malignancies
hepatobiliary cancer
pancreatic cancer
issues in oncology

Abdominal Blood Clots May Indicate Undiagnosed Cancer

New research published by Søgaard et al in Blood found that blood clots in the abdominal veins might be an indicator of undiagnosed cancer. The study also suggests that these clots predict poorer survival in patients with liver and pancreatic cancer. Clotting and Cancer Risk Compared to...

pancreatic cancer
survivorship

National Cancer Database Analysis Identifies Characteristics of 10-Year Survivors of Pancreatic Ductal Adenocarcinoma

In an analysis reported in JAMA Surgery, Paniccia et al identified patient and treatment characteristics that were associated with survival of at least 10 years after diagnosis of invasive pancreatic ductal adenocarcinoma, including lower positive lymph node ratio, receipt of adjuvant chemotherapy, ...

palliative care
pancreatic cancer
issues in oncology

Two Studies Highlight Benefit of Stereotactic Body Radiotherapy in Locally Advanced Pancreatic Cancer

Two studies from researchers at Johns Hopkins Kimmel Cancer Center add to preliminary evidence that high-dose radiation treatment, or stereotactic body radiotherapy, appears to be safe and as effective as standard radiation treatment for certain patients with locally advanced pancreatic cancer....

pancreatic cancer

Pazopanib Plus Octreotide Active in Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

In a phase II study reported in The Lancet Oncology, Phan et al found that the VEGFR-1, -2, -3 inhibitor pazopanib (Votrient) plus depot octreotide produced responses in patients with advanced well-differentiated neuroendocrine tumors. No responses were observed in patients with carcinoid tumors....

palliative care
pancreatic cancer
supportive care

German Trial Shows Reduced Risk of Venous Thromboembolism With Prophylactic Enoxaparin in Ambulatory Patients With Advanced Pancreatic Cancer

In the German CONKO-004 trial reported in the Journal of Clinical Oncology, Pelzer et al found that prophylactic treatment with the low-molecular-weight heparin enoxaparin reduced the risk of symptomatic venous thromboembolic events in ambulatory patients receiving first-line chemotherapy for...

pancreatic cancer
issues in oncology

Germline BRCA Mutations Found in Almost 5% of Patients With Pancreatic Adenocarcinoma

In a study reported in the Journal of Clinical Oncology, Holter et al found that 4.6% of a large clinic population of patients with pancreatic adenocarcinoma harbored pathogenic germline BRCA mutations. The study involved analysis of 306 unselected, consecutive, incident patients with pancreatic...

pancreatic cancer

FDA Grants Fast Track Designation to Evofosfamide for Advanced Pancreatic Cancer

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of evofosfamide (TH-302), administered in combination with gemcitabine, for previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer. Evofosfamide is an...

pancreatic cancer

Weak Sunlight Exposure May Be a Risk Factor in Pancreatic Cancer

Researchers at University of California San Diego School of Medicine recently found that pancreatic cancer rates are highest in countries with the least amount of sunlight. These findings were published by Garland et al in The Journal of Steroid Biochemistry and Molecular Biology. “If...

pancreatic cancer

AACR 2015: Metformin Use May Not Improve Pancreatic Cancer Survival

Metformin use did not improve survival of patients with pancreatic ductal adenocarcinoma in a retrospective cohort study presented at the AACR Annual Meeting 2015, held April 18 to 22 in Philadelphia (Abstract LB-183). “The diabetes drug metformin is being used in some cancer treatment...

palliative care
gynecologic cancer
pancreatic cancer
solid tumors

AACR 2015: Investigational CART-meso Immunotherapy Feasible for Patients With Advanced Cancers

Patients with advanced cancers who received mesothelin-directed chimeric antigen receptor–modified T cells (CART-meso), a type of investigational adoptive immunotherapy, tolerated the treatment well, and there was evidence that the infused immune cells persisted in the patients’ blood...

pancreatic cancer

Improved Quality Metrics for Robotic Pancreaticoduodenectomy With Increased Performance

In a retrospective single-institution study reported in JAMA Surgery, Boone et al found significant improvements in blood loss, incidence of conversion to open surgery, pancreatic fistula incidence, and operative time with increased number of patients treated with robotic pancreaticoduodenectomy....

pancreatic cancer

American Gastroenterological Association Releases New Guidelines on the Management of Asymptomatic Neoplastic Pancreatic Cysts

The growing use of sophisticated abdominal imaging techniques, which has led to a marked increase in the findings of incidental pancreatic cysts, has prompted the American Gastroenterological Association (AGA) to issue new recommendations in the management of asymptomatic neoplastic pancreatic...

pancreatic cancer
supportive care
palliative care

Palliative Care Consultation Associated With Less Aggressive End-of-Life Care in Advanced Pancreas Cancer

In a study reported in the Journal of the National Cancer Institute, Jang et al found that palliative care consultation was associated with decreased use of chemotherapy near death and lower risks of ICU admission, multiple emergency department visits, and multiple hospitalizations near death in...

pancreatic cancer

Study Shows Targeting Cancer Cell ‘Cloak’ Could Benefit Drug Delivery

Cancer cells can cloak themselves within tumors by hiding behind a dense layer of cellular stroma. According to a new study by the Translational Genomics Research Institute (TGen), drugs that target and strip away the stroma would pave the way for other drugs to reach the cancerous cells within the ...

lung cancer
pancreatic cancer
issues in oncology

Chemotherapy Trials for Advanced Cancers of the Lung and Pancreas Overestimate Survival for Elderly Medicare Patients

Results of clinical trials evaluating chemotherapy regimens for advanced pancreatic cancer and lung cancers “tended to correctly estimate survival for Medicare patients aged 65 to 74 years, but to overestimate survival for older Medicare patients by 6 to 8 weeks,” Lamont et al reported...

pancreatic cancer

Reduced Use of Radiotherapy for Unresectable Pancreatic Adenocarcinoma in the United States

In a study reported in a research letter in JAMA Surgery, Shapiro et al found that use of radiotherapy in unresectable pancreas cancer has decreased over time and that disparities in use can be identified. Decreasing Use The study involved Surveillance, Epidemiology, and End Results (SEER) data...

issues in oncology
pancreatic cancer
issues in oncology

Study Finds Biologic Markers Associated With High-Risk Pancreatic Lesions

Pancreatic cancer affects approximately 46,000 people each year in the United States, and ranks fourth among the leading causes of cancer-related deaths. Only about 6% of individuals with pancreatic cancer will live 5 years after their diagnosis. One reason for this high mortality rate is the lack...

cns cancers
pancreatic cancer
issues in oncology
sarcoma

Researchers Identify Potential Treatment Targeting Proliferation Pathway in Some Aggressive Tumors

Researchers from the Massachusetts General Hospital (MGH) Cancer Center and Boston University School of Medicine (BUSM) have identified a potential treatment targeting a pathway by which several aggressive tumors maintain their ability to proliferate, according to a study by Flynn et al published...

issues in oncology
cns cancers
cns cancers
pancreatic cancer
issues in oncology
solid tumors

ATRX Mutation Linked to Brain and Pancreatic Neuroendocrine Tumors May Be Biomarker for Rare Adrenal Tumors

A somatic mutation in the ATRX gene has recently been identified as a potential molecular marker for gliomas, neuroblastomas, and pancreatic neuroendocrine tumors. Now, researchers at the Perelman School of Medicine at the University of Pennsylvania have found that the same mutated gene may serve...

pancreatic cancer

Prime-Boost Vaccine Increases Survival in Metastatic Pancreas Cancer

In a study reported in the Journal of Clinical Oncology, Le et al found that adding Listeria monocytogenes–expressing mesothelin (CRS-207) boost to GVAX pancreas vaccine priming resulted in improved overall survival in patients with previously treated metastatic pancreas adenocarcinoma....

hepatobiliary cancer
pancreatic cancer

Two Combination Studies Demonstrate Safety and Survival Benefit for VT-122 in Liver and Pancreatic Cancers

The immunooncology company Vicus Therapeutics announced the presentation of two separate studies demonstrating a safety and survival benefit for VT-122, the company's lead compound, when combined with standard-of-care therapy in patients with advanced liver and pancreatic cancers. Results from both ...

pancreatic cancer

Expanded Analyses of Phase III MM-398 NAPOLI-1 Study Substantiate Positive Results of MM-398 Combined With Fluorouracil/Leucovorin

Additional analyses from the global phase III NAPOLI-1 study of MM-398 (aka PEP02), a nanoliposomal encapsulation of irinotecan, in metastatic pancreatic cancer were presented by Chen et al in an oral session at the 2015 Gastrointestinal Cancers Symposium  (Abstract 234). The primary analysis ...

pancreatic cancer

Modified Pancreatic Cancer Regimen Maintains Effectiveness While Reducing Side Effects and Cost

A simple change to a two-drug therapy for metastatic pancreatic cancer provides similar cancer control while significantly improving quality of life and reducing the cost of care, according to data reported by researchers at the The Ohio State University Comprehensive Cancer Center – Arthur...

pancreatic cancer

Addition of Hypoxia-Activated Prodrug TH-302 to Gemcitabine Improves Progression-Free Survival in Advanced Pancreas Cancer

TH-302 is a hypoxia-activated prodrug that releases the DNA alkylator bromo-isophosphoramide mustard in hypoxic settings. In a phase II trial reported in the Journal of Clinical Oncology, Borad et al found that the addition of TH-302 to gemcitabine improved progression-free survival in patients...

pancreatic cancer

Long-Term Diabetes Associated With Increased Mortality in Pancreas Cancer

In a study reported in the Journal of Clinical Oncology, Yuan et al found that pancreas cancer patients with diabetes of more than 4 years’ duration at diagnosis had significantly poorer survival compared with nondiabetic patients. Study Details The study involved data from 1,006 patients...

pancreatic cancer

Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of necuparanib as a first-line treatment in combination with paclitaxel and gemcitabine in patients with metastatic pancreatic cancer. Necuparanib is a novel oncology drug candidate engineered from...

hepatobiliary cancer
pancreatic cancer

Regional Hepatopancreaticobiliary Surgical Program Improves Care in VA System

In a retrospective cohort study reported in JAMA Surgery, Lau et al found that implementation of a multidisciplinary hepatopancreaticobiliary surgical program in a Veterans Affairs (VA) health-care region resulted in improved care and outcomes. The study involved analysis of practices and outcomes ...

pancreatic cancer

FDA Grants Orphan Drug Designation to Investigational Agent for Pancreatic Cancer

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to pegylated recombinant human hyaluronidase (PEGPH20) for the treatment of pancreatic cancer. Halozyme Therapeutics is currently investigating PEGPH20 in a phase II study in combination with gemcitabine and...

cns cancers
pancreatic cancer

ESMO 2014: Everolimus Improves Overall Survival in Patients With Advanced Pancreatic Neuroendocrine Tumors

In a phase III trial, treatment with everolimus (Afinitor) resulted in a median overall survival of over 3 and a half years in patients with well-differentiated and progressive pancreatic neuroendocrine tumors, representing what the study authors called a "clinically important" although not...

pancreatic cancer

Boost in Plasma Levels of Chain Amino Acids Is Associated With Increased Risk of Pancreatic Cancer

In a recent study reported in Nature Medicine, scientists from Dana-Farber Cancer Institute, the Massachusetts Institute of Technology, and the Harvard School of Public Health, among other institutions, investigated whether pancreatic ductal adenocarcinoma produces metabolic changes that can be...

pancreatic cancer

Baseline Vitamin D Not Associated With Survival in Patients With Advanced Pancreatic Cancer in CALGB 80303/Alliance Trial

Preclinical data indicate a role of vitamin D metabolism in pancreatic tumor development. In a study reported in the Journal of the National Cancer Institute, Van Loon et al found that baseline serum 25-hydroxyvitamin D (25[OH]D) levels were not associated with progression-free survival or overall...

pancreatic cancer
issues in oncology

Genome-Wide Association Study Finds New Genetic Risk Markers in Pancreatic Cancer

A large DNA analysis of people with and without pancreatic cancer has identified several new genetic markers that signal increased risk of developing the highly lethal disease, reported scientists from Dana-Farber Cancer Institute. The study by Wolpin et al was published in Nature Genetics. The...

pancreatic cancer

Adding Oxaliplatin to Leucovorin/Fluorouracil Increases Survival in Second-Line Treatment of Gemcitabine-Refractory Pancreatic Cancer

In the German phase III CONKO-003 trial reported in the Journal of Clinical Oncology, Oettle et al found that second-line oxaliplatin, leucovorin, and fluorouracil (5-FU) significantly increased overall survival and time to progression vs leucovorin/5-FU in patients with advanced pancreatic cancer...

pancreatic cancer

No Benefit of Adding Telomerase Peptide Vaccine to Chemotherapy in Patients With Advanced Pancreatic Cancer

In a UK phase III TeloVac trial reported in The Lancet Oncology, Middleton et al found that the sequential or concurrent addition of the telomerase peptide vaccine GV1001 to gemcitabine/capecitabine did not improve survival in patients with locally advanced or metastatic pancreatic cancer. GV1001...

Advertisement

Advertisement



Advertisement